Source: CNBC
KEY POINTS
- Novavax said it expects to finalize an agreement that would see it begin to supply Canada with doses “as early as the second quarter of 2021,” the company said.
- The company’s vaccine, called NVX-CoV2373, is currently in phase two trials.
- Novavax has previously said it could begin late-stage trials as early as October.
American vaccine developer Novavax announced Monday that it’s reached an agreement in principle with Canada to supply 76 million doses of its experimental coronavirus vaccine to the country.
The company said it expects to finalize an agreement to supply Canada with doses “as early as the second quarter of 2021.” The agreement is contingent on the vaccine getting a license from Health Canada, the company said.
Shares of Novavax rose nearly 2% in early morning trading on the news.
The company’s vaccine, called NVX-CoV2373, is currently in phase two trials. It has previously said it could begin late-stage trials as early as October.
“We are moving forward with clinical development of NVX-CoV2373 with a strong sense of urgency in our quest to deliver a vaccine to protect the world,” Novavax CEO Stanley Erck said in a statement.
The company did not disclose the financial terms of the agreement.
“This is an important step in our government’s efforts to secure a vaccine to keep Canadians safe and healthy, as the global pandemic evolves,” Anita Anand, Canada’s minister of public services and procurement, said in a statement.
The agreement is the latest example of countries, particularly wealthier Western nations, rushing to secure doses of a potential vaccine for the coronavirus, which has infected more than 25.2 million people around the world and killed at least 846,900 people, according to data compiled by Johns Hopkins University. Canada previously announced similar deals with Pfizer and Moderna, two front-runners in the race for a vaccine.
Categories: Vaccine
AstraZeneca Plc has begun a large-scale human trial of its coronavirus vaccine in the U.S. following a brief delay, according to researchers from the University of Wisconsin School of Medicine and Public Health who are helping conduct the tests.
The university, one of the sites for the 30,000 person trial, plans to begin injecting healthy volunteers on Tuesday, according to William Hartman, a UW Health anesthesiologist and investigator on the trial. It plans to ramp up to injecting 50 people a day shortly after the Sept. 7 Labor Day holiday, he said in an interview.
AstraZeneca didn’t immediately respond to a request for comment.
The AstraZeneca shot, invented by researchers at the University of Oxford, is one of the farthest along of numerous Covid-19 vaccines in development. In addition to the U.S. trial, a final-stage test of the inoculation is underway in the U.K. and could yield preliminary results as soon as next month. Other companies that have Covid-19 vaccines in phase 3 trials include Moderna Inc. and Pfizer Inc.
https://www.bloomberg.com/news/articles/2020-08-31/astrazeneca-u-s-vaccine-trial-starts-after-delay-hospital-says?srnd=premium&sref=eGA8az79
Reblogged this on Alexanders' Blog.
(CNN)Early stage clinical trial results show the Covid-19 vaccine candidate made by Novavax is safe and elicits an immune response, according to a study published Wednesday in The New England Journal of Medicine. The results had previously been announced by the company in early August.
What we've learned about Covid-19 seven months after the first US case
What we’ve learned about Covid-19 seven months after the first US case
Using a randomized, placebo-controlled trial — the gold-standard method of study — scientists gave the vaccine or a placebo, an inert substance like saline, to 131 healthy adults in May. Eighty-three people got the vaccine with adjuvant, an agent to boost the body’s immune response. Another 25 got the vaccine without the booster and 23 got the placebo. Participants also received a second injection 21 days after the first.
The volunteers came from two locations in Australia and they were all under the age of 60. People who had Covid-19 or who had recovered from Covid-19 were excluded from the trial.
https://www.cnn.com/2020/09/02/health/novavax-vaccine-safe/index.html